BIIB
Biogen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Below Expectations
Revenue Below Expectations
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BIIB
Biogen Inc.
One of the world's first global biotech companies and develops treatments for neurodegenerative, autoimmune and heatologic disorders
225 Binney Street, Cambridge, MA 02142
Manufacture and sale of medicines for the treatment of multiple sclerosis
Biogen Inc., founded in California in 1985 as IDEC Pharmaceuticals, Inc., was re-registered as a Delaware corporation in 1997. In 2003, Biogen, Inc., was acquired and the company name was changed to Biogen Idec Inc. The Company is a global biopharmaceutical company focused on discovering, developing and delivering global innovative therapies for patients with severe neurological and neurodegenerative diseases and related therapeutic adjacent patients. The company's core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular diseases, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. The company is also focused on discovering, developing and delivering global innovative therapies in emerging growth areas such as immunology, neurocognitive disorders, acute neurology and pain.
Earnings Call
Q1/2025
Estimate EPS2.96
Actual EPS3.02
Estimate Revenue2.23B
Actual Revenue2.43B
Biogen's Q1 2025: Unraveling Contradictions on LEQEMBI Launch, Reimbursement, and Market Strategy
May 13,2025 11:09
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS3.88
Actual EPS5.47
Estimate Revenue2.32B
Actual Revenue2.65B
Biogen's Q2 2025 Earnings Call: Key Contradictions in LEQEMBI's Market Share, Pipeline Strategy, and Alzheimer’s Diagnostics
Jul 31,2025 02:36
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS3.88
Actual EPS4.81
Estimate Revenue2.34B
Actual Revenue2.53B
Biogen's Q3 2025: Contradictions Emerge on LEQEMBI Administration, Alzheimer's Trial and Market Dynamics, and External Business Development Strategy
Oct 30,2025 11:48
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BIIB has released its 2025 Q3 earnings. EPS was reported at 4.81, versus the expected 3.88, beating expectations. The chart below visualizes how BIIB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BIIB has released its 2025 Q3 earnings report, with revenue of 2.53B, reflecting a YoY change of 2.79%, and net profit of 466.50M, showing a YoY change of 20.08%. The Sankey diagram below clearly presents BIIB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
